I read with interest the article written by Beck et al.
I read with interest the article written by Beck et al.
1 about the outcomes of their patients with B-precursor ALL and BM relapse who received allogeneic hematopoietic SCT (allo-HSCT). In the abstract, the authors concluded that their results suggested that allo-HSCT should be pursued in children after a first marrow relapse rather than waiting for subsequent recurrence. I am very concerned about this potentially misleading conclusion because it was based on comparison of patients in second remission (CR2) with patients in third remission (CR3), and such comparison is fraught with important biases.
The authors demonstrated that patients transplanted in CR2 had significantly better disease-free survival (DFS) and lower cumulative incidence of relapse compared with patients transplanted in CR3. Such results are indeed expected, as patients who relapse after treatment are more likely to have aggressive or resistant disease, and therefore patients in CR2 (whether following early or late relapse) can be expected to have worse outcome compared with patients in CR1. Similarly, patients in CR3 or CR4 are expected to have even worse outcomes compared with patients in CR2, regardless of treatment received. As the biology of the leukemia in patients who relapse is different from that in patients who do not relapse, comparison of their clinical outcomes might just represent such a difference in leukemia behavior, but not whether early transplant is beneficial or not. To determine whether HSCT should be done in CR2, we need to compare the outcomes of patients in CR2 who received HSCT vs those in CR2 who received alternative therapy, for example, chemotherapy. This would best be done in a randomized controlled trial. As the authors rightly pointed out in the Discussion section, prospective clinical trials directly comparing unrelated donor transplantation with chemotherapy for patients with late-relapsed CR2 are needed.
Another bias of comparing patients in CR2 with CR3 stems from the selection of patients for HSCT. In the authors' cohort, 'the decision whether or not to perform allo-HSCT in CR3 vs CR2 was made by the referring physicians, and no further detail on decision criteria was provided. Selection bias would have occurred, if the patients transplanted in CR2 were systematically different from those not transplanted, and would result in apparent superiority of early transplant. Those who received HSCT in CR2 might have had better performance status and were free of infections, and hence better survival. To eliminate such selection bias, randomized comparisons would be required. However, this is not always possible as some patients would have no appropriate transplant donor or are too ill to go into the transplant. The second best option to evaluate whether ALL patients with late relapse should be transplanted in CR2 would be a prospective trial with well-defined selection criteria for HSCT to minimize systematic difference between patient groups.
Apart from inherent biological differences and selection biases that occur when comparing outcomes of CR2 and CR3, the third major problem is the likely presence of numerous potential confounding factors in such comparisons, including patients' performance status (generally worse with more relapses), organ dysfunction (also worse with more previous toxic therapies), degree of HLA matching (might be worse in late transplant group, as patients with well-matched donors might have been transplanted earlier), CMV status, stem cell source, conditioning regimen, GVHD prophylaxis and so on. All these important factors were highly variable in the authors' cohort and potentially confounded the results, causing spurious superiority of HSCT in CR2. This is suggested by the analyses that DFS was significantly different between CR2 and CR3 patients in univariate but not multivariate analyses where some of these confounders were taken into consideration.
In conclusion, comparing patients in CR2 with CR3 could not lead to valid answer about treatment options. Whether patients with late relapse of B-precursor ALL should receive unrelated donor HSCT in CR2 remains uncertain, and well-designed prospective trials comparing unrelated HSCT, family-donor HSCT and chemotherapy are urgently needed.
